![How ECCO's new Vitrus Mondial Collection Makes Formal Shoes Modern — And Comfortable - Sharp Magazine How ECCO's new Vitrus Mondial Collection Makes Formal Shoes Modern — And Comfortable - Sharp Magazine](https://sharpmagazine.com/wp-content/uploads/2020/05/HOM-2.jpg)
How ECCO's new Vitrus Mondial Collection Makes Formal Shoes Modern — And Comfortable - Sharp Magazine
![ECCO 2021 - New Data On Therapy For Severely Active Ulcerative Colitis by Health Professional Radio - Podcast ECCO 2021 - New Data On Therapy For Severely Active Ulcerative Colitis by Health Professional Radio - Podcast](https://d3t3ozftmdmh3i.cloudfront.net/production/podcast_uploaded_episode400/13383931/13383931-1627232736132-4dd7235fa5be1.jpg)
ECCO 2021 - New Data On Therapy For Severely Active Ulcerative Colitis by Health Professional Radio - Podcast
![Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists - Gastroenterology Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists - Gastroenterology](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/31ac3ad3-ea48-42bc-9e9f-23ccf71533ec/gr1_lrg.jpg)
Approach to the Management of Recently Diagnosed Inflammatory Bowel Disease Patients: A User's Guide for Adult and Pediatric Gastroenterologists - Gastroenterology
![Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study - Schmitz - 2018 - Alimentary Pharmacology & Therapeutics - Wiley Online Library Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study - Schmitz - 2018 - Alimentary Pharmacology & Therapeutics - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/f4535365-e3fc-49a4-98af-cec3692ff087/apt.2018.47.issue-3.cover.jpg)
Switching from infliximab innovator to biosimilar in patients with inflammatory bowel disease: a 12‐month multicentre observational prospective cohort study - Schmitz - 2018 - Alimentary Pharmacology & Therapeutics - Wiley Online Library
![Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective | Pharmacology Frontiers | An Update for Pharmacologists on New Treatment Options for Inflammatory Bowel Disease: The Clinicians' Perspective | Pharmacology](https://www.frontiersin.org/files/Articles/655054/fphar-12-655054-HTML-r1/image_m/fphar-12-655054-g001.jpg)